Version 1
: Received: 27 April 2021 / Approved: 28 April 2021 / Online: 28 April 2021 (10:23:12 CEST)
How to cite:
Dewanjee, S.; Vallamkondu, J.; Chakraborty, P.C.; Kalra, R.; Gangopadhyay, M.; Sahu, R.; Medala, V.; John, A.; Reddy, P.H.; Kandimalla, R. The Emerging role of HDACs: Pathology and Therapeutic targets in Diabetes Mellitus. Preprints2021, 2021040742. https://doi.org/10.20944/preprints202104.0742.v1
Dewanjee, S.; Vallamkondu, J.; Chakraborty, P.C.; Kalra, R.; Gangopadhyay, M.; Sahu, R.; Medala, V.; John, A.; Reddy, P.H.; Kandimalla, R. The Emerging role of HDACs: Pathology and Therapeutic targets in Diabetes Mellitus. Preprints 2021, 2021040742. https://doi.org/10.20944/preprints202104.0742.v1
Dewanjee, S.; Vallamkondu, J.; Chakraborty, P.C.; Kalra, R.; Gangopadhyay, M.; Sahu, R.; Medala, V.; John, A.; Reddy, P.H.; Kandimalla, R. The Emerging role of HDACs: Pathology and Therapeutic targets in Diabetes Mellitus. Preprints2021, 2021040742. https://doi.org/10.20944/preprints202104.0742.v1
APA Style
Dewanjee, S., Vallamkondu, J., Chakraborty, P.C., Kalra, R., Gangopadhyay, M., Sahu, R., Medala, V., John, A., Reddy, P.H., & Kandimalla, R. (2021). The Emerging role of HDACs: Pathology and Therapeutic targets in Diabetes Mellitus. Preprints. https://doi.org/10.20944/preprints202104.0742.v1
Chicago/Turabian Style
Dewanjee, S., P. Hemachandra Reddy and Ramesh Kandimalla. 2021 "The Emerging role of HDACs: Pathology and Therapeutic targets in Diabetes Mellitus" Preprints. https://doi.org/10.20944/preprints202104.0742.v1
Abstract
Diabetes mellitus (DM) is one of the principal manifestations of metabolic syndrome and its prevalence with modern lifestyle is increasing incessantly. Chronic hyperglycemia can induce several vascular complications that were referred to be the major cause of morbidity and mortality in DM. Although several therapeutic targets have been identified and accessed clinically, the imminent risk of DM and its prevalence are still ascending. Substantial pieces of evidence revealed that histone deacetylase (HDAC) isoforms can regulate various molecular activities in DM via epigenetic and post-translational regulation of several transcription factors. To date, 18 HDAC isoforms have been identified in mammals that were categorized into 4 different classes. Classes I, II, and IV are regarded as classical HDACs, which operate through a Zn-based mechanism. In contrast, class III HDACs or Sirtuins depend on nicotinamide adenine dinucleotide (NAD+) for their molecular activity. Functionally, most of the HDAC isoforms can regulate β cell fate, insulin release, insulin expression and signaling, and glucose metabolism. Moreover, the roles of HDAC members have been implicated in the regulation of oxidative stress, inflammation, apoptosis, fibrosis, and other pathological events, which substantially contribute to diabetes-related vascular dysfunctions. Therefore, HDACs could serve as the potential therapeutic target in DM towards developing novel intervention strategies. This review sheds light on the emerging role of HDACs/isoforms in diabetic pathophysiology and emphasized the scope of their targeting in DM for constituting the novel interventional strategies for metabolic disorders/complications.
Medicine and Pharmacology, Endocrinology and Metabolism
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
,
